Potency-Guided Tumor-Infiltrating Lymphocyte Therapy in Metastatic Uveal Melanoma: A Phase 2 Trial
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) produces durable responses in metastatic cutaneous melanoma, but its activity in less immunogenic cancers remains uncertain. We conducted a single-center, single-arm phase 2 trial of potency-guided TIL therapy in metastatic uveal melanoma, an immunotherapy-resistant cancer. Primary TIL cultures from resected metastases were screened for autologous tumor reactivity before selective expansion for treatment. Thirty-three predominantly pretreated patients received nonmyeloablative lymphodepletion, autologous TIL, and high-dose interleukin-2. The primary endpoint was confirmed objective response rate (ORR); secondary endpoints were duration of response, progression-free survival (PFS), overall survival (OS), and safety. Among 32 response-evaluable patients, the ORR was 21.9% (95% CI, 9.3–40.0; one-sided 97.5% lower confidence bound, 9.3%), meeting the prespecified primary efficacy criterion. Median duration of response was 17.3 months (95% CI, 2.6 to not reached), with the longest response ongoing beyond 5 years. Median PFS was 4.6 months (95% CI, 2.8–5.5), and median OS was 13.7 months (95% CI, 8.1–20.4). Objective responses occurred exclusively among recipients of tumor-reactive infusion products (7 of 19 [36.8%] versus 0 of 12; P = 0.03), and this association was reproduced in a pooled analysis with an independent uveal melanoma TIL trial (12 of 28 [42.9%] versus 0 of 20; P < 0.001). All patients experienced reversible grade 4 hematologic adverse events attributable to lymphodepletion; no treatment-related deaths occurred. In exploratory analyses, Uveal Melanoma Immunogenomic Score (UMIS), a premanufacturing transcriptomic measure of tumor immune activity, was associated with tumor-reactive TIL generation, infusion-product reactivity, and clinical response. Potency-guided TIL therapy produced durable responses in metastatic uveal melanoma with expected and reversible toxicity, supporting functional tumor-reactivity screening as a strategy for extending TIL therapy to cancers with low intrinsic immunogenicity. ClinicalTrials.gov identifier: NCT03467516.
- Type: RNA Sequencing
- Archive: The database of Genotypes and Phenotypes (dbGaP)
